Arcturus Therapeutics’ (ARCT) Buy Rating Reiterated at HC Wainwright

Arcturus Therapeutics (NASDAQ:ARCT)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $63.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 173.56% from the company’s current price.

Several other equities analysts also recently weighed in on ARCT. Leerink Partners began coverage on Arcturus Therapeutics in a research report on Monday, August 12th. They issued an “outperform” rating and a $70.00 target price for the company. Leerink Partnrs raised Arcturus Therapeutics to a “strong-buy” rating in a research report on Monday, August 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Arcturus Therapeutics presently has an average rating of “Buy” and a consensus price target of $71.40.

Arcturus Therapeutics Trading Down 0.8 %

ARCT traded down $0.18 on Tuesday, hitting $23.03. The company had a trading volume of 162,174 shares, compared to its average volume of 486,860. The firm has a market cap of $620.24 million, a P/E ratio of -5.89 and a beta of 2.60. Arcturus Therapeutics has a 1 year low of $17.52 and a 1 year high of $45.00. The company’s fifty day moving average price is $20.90 and its 200 day moving average price is $26.41.

Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($1.85) by $1.21. The company had revenue of $49.86 million during the quarter, compared to the consensus estimate of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same period in the previous year, the company posted ($1.98) EPS. On average, analysts predict that Arcturus Therapeutics will post -2.6 earnings per share for the current year.

Institutional Investors Weigh In On Arcturus Therapeutics

Large investors have recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new stake in shares of Arcturus Therapeutics in the 1st quarter valued at approximately $40,000. Quest Partners LLC raised its stake in Arcturus Therapeutics by 3,283.5% during the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 3,579 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its position in Arcturus Therapeutics by 10.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 428 shares during the last quarter. Public Employees Retirement System of Ohio boosted its stake in Arcturus Therapeutics by 63.8% in the first quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company’s stock valued at $156,000 after acquiring an additional 1,800 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Arcturus Therapeutics by 66.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 5,153 shares of the biotechnology company’s stock worth $174,000 after purchasing an additional 2,064 shares during the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.